Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Edwards, J.; Krishna, N.S.; Mukherjee, R.; Watters, A.D.; Underwood, M.A.; Bartlett, J.M.S. (2001)
Publisher: Blackwell Publishing
Languages: English
Types: Article
Subjects: RC0254, RB
Objective To examine the role of androgen receptor (AR) gene amplification and aneusomy of the X chromosome in the development of antiandrogen-resistant prostate cancer. Patients and methods Twenty patients with prostate cancer resistant to androgen-deprivation therapy were selected for study. The records of patients with tumours before and after antiandrogen therapy, and with a full clinical follow-up, were retrieved. AR gene amplification and X chromosome copy number were assessed by fluorescence in situ hybridization using a labelled probe at locus Xq11-13 for the AR gene and a labelled a-satellite probe for the X chromosome. At least 20 nuclei were scored over three tumour areas by two independent observers. Results Aneusomy of the X chromosome was reported respectively in seven (35%) and 11 (55%) tumours before and after hormone relapse, the AR gene copy number was increased in seven (35%) and 13 (65%), respectively, and AR gene amplification was detected in one (5%) and three (15%), respectively. Neither increased AR copy number nor AR amplification in primary tumours precluded a biological response to androgen-deprivation therapy. Conclusion The rate of AR gene amplification is too low to be solely responsible for the development of antiandrogen-resistant prostate cancer. Also, the presence of amplified AR and cells aneusomic for the X chromosome in primary tumours that respond to androgen-deprivation therapy suggests that an increase in AR gene copy number does not prevent a tumour from responding to this therapy. Therefore other mechanisms which could cause hormone-refractory prostate cancer must be investigated before it is understood why so many patients relapse with this disease.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 Goktas S, Ziada A, Crawford ED. Combined androgen blockade for advanced prostatic carcinoma. Prostate Cancer Prostatic Dis 1999; 2: 172±9
    • 2 Maraj BH, Markham AF. Prostate-speci®c membrane antigen (FOLH1): recent advances in characterising this putative prostate cancer gene. Prostate Cancer Prostatic Dis 1999; 2: 180±5
    • 3 McLeod DG, Crawford ED, DeAntoni EP. Combined androgen blockade: The gold standard for metastatic prostate cancer. Euro Urol 1997; 32 (Suppl. 3): 70 ±7
    • 4 Gregory CW, Hamil KG, Kim D et al. Androgen receptor expression in androgen independent prostate cancer is associated with increased expression of androgen regulated genes. Cancer Res 1998; 58: 5718±24
    • 5 Kemppainen JA, Lane MA, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. J Biol Chem 2000; 267: 968±74
    • 6 Trapman J, Brinkmann AO. The androgen receptor in prostate cancer. Pathology Res Prac 1996; 192: 752 ±60
    • 7 Giovannucci E, Stampfer MJ, Krithivas K et al. Erratum: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 8272±81
    • 8 Newling D, Fossa SD, Andersson L et al. Assessment of hormone refractory prostate cancer. Urology 1997; 49 (Suppl. 4A): 46 ±53
    • 9 Visakorpi T, Hytinen E, Koivisto P et al. In vivo ampli®cation of the androgen receptor gene and progression of human prostate cancer. Nature Genet 1995; 9: 401±6
    • 10 Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene ampli®cation: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314 ±9
    • 11 Miyoshi Y, Uemura H, Fujinami K et al. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene ampli®cation and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 2000; 43: 225 ±32
    • 12 Bubendorf L, Kononen J, Koivisto P et al. Survey of gene ampli®cations during prostate cancer progression by high throughput ¯uorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59: 803±6
    • 13 Bartlett JMS, Watters AD, Ballantyne SA, Going JJ, Grigor KM, Cooke TG. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? BJC 1998; 77: 2193±8
    • 14 Fronsdal K, Engedal N, Slagsvold T, Saatcioglu F. CREB binding protein is a co-activator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 1998; 273: 31 853±9
    • 15 Sadar MD. Androgen independent induction of prostate speci®c antigen gene expression via cross talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999; 274: 7777±83
    • 16 Sadar MD, Hussain M, Bruchovsky N. Prostate cancer; molecular biology of early progression to androgen independence. Endocrine Related Cancer 1999; 6: 487±502
    • 17 Sato N, Sadar MD, Bruchovsky N et al. Androgenic induction of prostate-speci®c antigen gene is repressed by protein±protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 1997; 272: 17 485±94
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article